Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Payables: 2009-2024

Historic Payables for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $45.7 million.

  • Ani Pharmaceuticals' Payables rose 14.62% to $69.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $223.1 million, marking a year-over-year increase of 14.00%. This contributed to the annual value of $45.7 million for FY2024, which is 24.46% up from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Payables is $45.7 million, which was up 24.46% from $36.7 million recorded in FY2023.
  • Over the past 5 years, Ani Pharmaceuticals' Payables peaked at $45.7 million during FY2024, and registered a low of $11.3 million during FY2020.
  • Its 3-year average for Payables is $37.2 million, with a median of $36.7 million in 2023.
  • In the last 5 years, Ani Pharmaceuticals' Payables fell by 22.90% in 2020 and then skyrocketed by 103.95% in 2021.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Payables stood at $11.3 million in 2020, then surged by 103.95% to $23.0 million in 2021, then rose by 27.60% to $29.3 million in 2022, then increased by 25.18% to $36.7 million in 2023, then grew by 24.46% to $45.7 million in 2024.